Figures & data
Figure 1. Enrolment of study participants.
Table I. Patient and tumor characteristics (intention-to-treat population).
Figure 2. Recurrence-free survival (RFS) since the date of randomization of patients with HER2-positive breast cancer. Upper panel: RFS by treatment with adjuvant trastuzumab; Lower panel: RFS by the duration of adjuvant trastuzumab. The five-year survival figures are shown. Patients who were censored are indicated with a bar.
Table II. Characteristics of patients and tumors treated with different durations of adjuvant trastuzumab.
Figure 3. Recurrence-free survival of patients with HER2-positive breast cancer treated with docetaxel (T) followed by cyclophosphamide, epirubicin and fluorouracil (CEF) or with docetaxel and capecitabine (TX) followed by cyclophosphamide, epirubicin and capecitabine (CEX) with or without trastuzumab.
